One of the biggest fears people have about growth hormone compounds is “GH face” — the idea that elevated growth hormone will permanently change your facial structure, making your jaw wider and your forehead more prominent. This fear is dramatically overblown for anyone using GH secretagogues at Natty Plus doses.
What Causes Acromegaly-Like Features
True acromegalic facial changes — brow ridge growth, jaw widening, hand and foot enlargement — result from chronically elevated GH and IGF-1 at levels far beyond physiological norms, sustained over years. We are talking about pituitary tumors producing 5-10x normal GH output, or bodybuilders injecting massive doses of pharmaceutical GH for extended periods.
MK-677 at 10-25mg per day does not produce these levels of GH elevation. It increases GH within or slightly above the physiological range. The IGF-1 increases are meaningful but nowhere near the territory that causes bone remodeling in adults. This is a key distinction explained by the Tony Huge Laws of Biochemistry Physics—dose-response non-linearity means you need a massive, sustained overload to trigger permanent structural changes.
Water Retention Is the Real Culprit
The facial changes that MK-677 users notice — puffier cheeks, softer jawline, slightly swollen appearance — are almost always water retention. GH promotes sodium and water retention, and the face is one of the first places it shows up because facial skin is thin and the tissue is loose.
The proof: these changes reverse completely within 1-2 weeks of discontinuing the compound. If it were bone growth, it would be permanent. If your face returns to normal after stopping MK-677, it was water — full stop.
When to Actually Worry
If you are using GH compounds and notice persistent hand numbness or tingling (carpal tunnel symptoms), shoe size increasing, or blood work showing IGF-1 levels significantly above the reference range, those are signs that your GH elevation may be excessive and dose reduction is warranted. These are dose-dependent effects that resolve with appropriate adjustment. Monitor IGF-1 on blood work and keep it within or near the upper end of the reference range — that is the sweet spot for benefits without excess.
Interesting Perspectives
The conversation around “GH face” often misses nuance. Some perspectives suggest that the transient facial puffiness from GH secretagogues might be partially mediated by histamine release or changes in subcutaneous fat distribution, not just fluid. Others in the biohacking community have noted that combining GH-supporting compounds with meticulous electrolyte and hydration protocols can significantly mitigate the water retention, turning a side effect into a manageable variable. Furthermore, the fear of permanent change ignores the body’s homeostatic resilience; true acromegalic bone growth requires a pathological breach of regulatory systems for years, not the pulsatile, moderated increase from a secretagogue.
Citations & References
- Melmed S. Acromegaly. N Engl J Med. 2006;355(24):2558-2573. (Describes the pathology of chronic GH excess leading to bone and soft tissue changes).
- Chapman IM, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81(12):4249-4257. (Shows MK-677 increases GH/IGF-1 within physiological range).
- Copinschi G, et al. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. J Clin Endocrinol Metab. 1996;81(8):2776-2782. (Demonstrates the pulsatile, non-pathological GH release pattern from MK-677).
- Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152-177. (Reviews GH’s metabolic actions, including sodium and water retention).
- Colao A, et al. Bone and joint complications in patients with acromegaly. J Endocrinol Invest. 2005;28(8 Suppl):12-17. (Details the long-term bone remodeling effects of pathological GH levels).